New drug IBI3003 enters first human trials for Hard-to-Treat multiple myeloma

NCT ID NCT07336472

Not yet recruiting Disease control Sponsor: Fortvita Biologics (USA)Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new drug called IBI3003 in about 360 people with multiple myeloma that has returned or no longer responds to standard treatments. The study has two parts: first, finding the safest and most effective dose, and then testing how well it works. Participants will receive the drug for up to 24 months or until their disease gets worse or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI3003 (a drug given intravenously)
What this could lead to: If successful, this could provide a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is a very early first-in-human study, so the drug may not work or could cause serious side effects. It is also not a cure, as treatment continues indefinitely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.